Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06377007

Refractive Outcomes and Ocular Biometry of Two Swept-Source Optical Coherence Tomography-Based Biometers With Segmental or Equivalent Refractive Indices (ORION)

Refractive Outcomes and Ocular Biometry of Two Swept-Source Optical Coherence Tomography-Based Biometers With Segmental or Equivalent Refractive Indices (ORION): A Non-Inferiority Randomized Clinical Trials

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
142 (estimated)
Sponsor
Walailak University · Academic / Other
Sex
All
Age
50 Years – 85 Years
Healthy volunteers
Accepted

Summary

Cataract surgery represents a common surgical intervention, encompassing the extraction of the opaque natural crystalline lens, followed by the substitution with an artificial intraocular lens (IOL). To ascertain an IOL possessing optimal power, antecedent to the surgery, preoperative evaluations are conducted through the utilization of a biometric devices. Diverse categories of these instruments are accessible, each harnessing distinct optical methodologies or mathematical algorithms to ascertain the most fitting IOL power. The principal objective of this study was to evaluate the ocular biometry and the predictive precision outcome of a biometer that uses standard keratometry to the prediction accuracy of another biometer that uses Total Keratometry.

Detailed description

Two swept-source optical coherence tomography (SS-OCT) biometers, namely the Argos and the IOLMaster 700, will be employed for the preoperative assessment of the eyes of all subjects who will undergo cataract surgery at the Eye Outpatient Department (OPD) of Walailak University Hospital. The sequence of biometry measurements will be randomized among the subjects. In Group 1, measurements will be initially conducted using the Argos device, followed by the IOLMaster 700 device. Conversely, Group 2 subjects will undergo measurements with the IOLMaster 700 device first, followed by the Argos device. The sequence will be continuous without any breaks. The analysis will encompass the right eyes of each subject. For the purpose of preoperative planning, the Argos device will utilize the Barrett Universal Formula II "K," whereas the IOLMaster 700 device will employ the Barrett Universal II TK formula. The objective for all eyes will be to achieve a plano outcome. In instances where the suggested intraocular lens (IOL) power differs between the two biometers, the IOL power recommended by the IOLMaster 700 device will be selected. Cataract surgeries will be exclusively performed by a seasoned surgeon (SM), who will adhere to a consistent approach involving a clear temporal incision (2.75 mm) followed by manual capsulorhexis. Refractive and visual outcomes will be evaluated within a postoperative timeframe of 28 to 42 days. Subjective refractions will be conducted by an optometrist, ensuring blinding to the biometry data. The primary endpoint of this study will be the mean absolute prediction error exhibited by each SS-OCT biometer. The computation of the absolute prediction error will involve determining the absolute disparity between the predicted spherical equivalent refraction derived from preoperative planning and the actual measured spherical equivalent refraction (manifest). Secondary objectives will encompass the median absolute prediction error and the proportion of eyes with an absolute prediction error equal to or less than 0.25 D and 0.5 D.

Conditions

Interventions

TypeNameDescription
DEVICEIOLMaster 700 (Carl Zeiss Meditec AG)Subjects will undergo measurements with the IOLMaster 700 device.
DEVICEArgos (Alcon Laboratories, Inc.)Subjects will undergo measurements with the Argos device.

Timeline

Start date
2024-01-01
Primary completion
2025-07-30
Completion
2025-12-30
First posted
2024-04-22
Last updated
2024-04-26

Locations

1 site across 1 country: Thailand

Source: ClinicalTrials.gov record NCT06377007. Inclusion in this directory is not an endorsement.